Étiquette : interaction CBD/THC

A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules, Gabriella Gobbi, 2019

A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules Gabriella Gobbi THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, VOL. 20, NO. 2, 98–100 Commentary https://doi.org/10.1080/15622975.2019.1584680   Along with tetrahydrocannabinol (THC), cannabidiol (CBD) is one of the main pharmacological components of Cannabis sativa and indica. Unlike THC, which binds CB1 receptors, CBD does not cause any dependence, and acts mostly via 5-HT1A and TPRV1 receptors (De Gregorio et al. 2018). Khoury et al. (2019) recently published a systematic review on the role of cannabidiol in psychiatry in the World Journal of Biological Psychiatry. After analysing 609 articles, they found six case reports, [...]

Lire la suite

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function, Celia J. A. Morgan et al., 2018

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha, Grainne Schafer, Chelsea Gardner and H. Valerie Curran Translational Psychiatry, 2018, 8, 181 DOI 10.1038/s41398-018-0191-x https://www.researchgate.net/publication/264860201   Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8mg, (iii) CBD [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L. Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]

Lire la suite

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation, Nadia SOLOWIJ et al., 2014,

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation Nadia SOLOWIJ, Samantha J. BROYD, Hendrika H. Van HELL, Arno HAZEKAMP BMC Pharmacol Toxicol, 2014, 15, 58 Published online 2014 Oct 16. doi: 10.1186/2050-6511-15-58 PMCID: PMC4274767 PMID: 25319497 Abstract Background Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆9-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical [...]

Lire la suite

Cannabidiol attenuates deficits of visuospatial associative memory induced by D9tetrahydrocannabinol, M. Jerry Wright Jr et al., 2013

Cannabidiol attenuates deficits of visuospatial associative memory induced by D9tetrahydrocannabinol M. Jerry Wright Jr, Sophia A. Vandewater and Michael A. Taffe Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA British Journal of Pharmacology, 2013, 170, 1365–1373   BACKGROUND AND PURPOSE Recent human studies suggest that recreational cannabis strains that are relatively high in cannabidiol (CBD) content produce less cognitive impairment than do strains with negligible CBD and similar D9tetrahydrocannabinol (THC) content. Self-selection in such studies means it is impossible to rule out additional variables which may determine both cannabis strain selection and basal cognitive performance level. Controlled laboratory studies can [...]

Lire la suite

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, Beckley Foundation, 2017.

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]

Lire la suite

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment, Ester Aso et al., 2019

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment Ester Aso, Víctor Fernández-Dueñas, Marc López-Cano, Jaume Taura, Masahiko Watanabe, Isidre Ferrer, Rafael Luján, Francisco Ciruela, Ester Aso Molecular Neurobiology, First Online: 04 January 2019, pp 1-10. C : Springer Nature Switzerland AG Abstract : At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can counteract the undesirable effects of the psychoactive cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) that hinder clinical development of cannabis-based therapies. Despite this attention, the mechanisms of CBD action and its interaction with Δ9-THC are still not completely elucidated. Here, by combining in vivo [...]

Lire la suite

Cannabis use and mental health : risks and benefits, Wayne HALL et al., 2019

Cannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019   In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]

Lire la suite

Cannabis, from plant to pill, Pr Christopher GROF, British Journal of Clinical Pharmacology, 2018, 84, 2463-2467

REVIEW-THEMED ISSUE Cannabis, from plant to pill Pr Christopher GROF, British Journal of Clinical Pharmacology, 2018, 84, 2463-2467 Correspondence Professor Christopher P. L. Grof, School of Environmental and Life Sciences, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia. Tel.: + 61 2 49215858; Fax: +61 2 4921 5361; 1 Centre for Plant Science, School of Environmental and Life Sciences, University of Newcastle, Newcastle, NSW 2308, Australia and 2 The Australian Centre for Cannabinoid Clinical and Research Excellence Hunter Medical Research Institute, Locked Bag 1000, New Lambton, NSW2305, Australia   Keywords : cannabinoids, cannabis, flos, flower, terpenoids   The therapeutic application of cannabis is attracting substantial public and clinical interest. [...]

Lire la suite